Brookstone Capital Management »

Black Diamond Therapeutics shares owned by Brookstone Capital Management

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by Brookstone Capital Management from 13F filings

Historical chart of Brookstone Capital Management investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by Brookstone Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by Brookstone Capital Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $30k 14k 2.13

More positions owned by Brookstone Capital Management

Vanguard Index Fds Value Etf (VTV)
Vanguard Index Fds Growth Etf (VUG)
NVIDIA Corporation (NVDA)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Apple (AAPL)
Ishares Tr Core S&p500 Etf (IVV)
Invesco Exch Traded Fd Tr Ii S&p500 Hdl Vol (SPHD)
Amazon (AMZN)
Northern Lts Fd Tr Iv Brookstone Grwth (BAMG)
Ishares Tr Core Msci Eafe (IEFA)
Ishares Tr Core Us Aggbd Et (AGG)
Northern Lts Fd Tr Iv Brookstone Value (BAMV)
Northern Lts Fd Tr Iv Brookstone Divid (BAMD)
Vanguard Index Fds S&p 500 Etf Shs (VOO)
Microsoft Corporation (MSFT)

View all positions for Brookstone Capital Management

Top funds holding Black Diamond Therapeutics

T. Rowe Price Investment Management
NEA Management Company
Vanguard Group
Acadian Asset Management
Marshall Wace
Siren
Arrowstreet Capital, Limited Partnership
Jane Street
Renaissance Technologies
BlackRock
Vestal Point Capital
Dimensional Fund Advisors
D. E. Shaw & Co
Connor, Clark & Lunn Investment Management
AWM Investment Company

View all funds holding Black Diamond Therapeutics